Cargando…

Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures

SIMPLE SUMMARY: The approval of the two antibody combinations trastuzumab/pertuzumab and ipilimumab/nivolumab in oncology has paved the way for novel antibody combinations or oligoclonal antibody mixtures to improve their efficacy in cancer. The underlying biological mechanisms and challenges of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larbouret, Christel, Gros, Laurent, Pèlegrin, André, Chardès, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465647/ https://www.ncbi.nlm.nih.gov/pubmed/34572847 http://dx.doi.org/10.3390/cancers13184620

Ejemplares similares

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

An oligoclonal combination of human monoclonal antibodies able to neutralize tetanus toxin in vivo
por: Aliprandini, Eduardo, et al.
Publicado: (2019)

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
por: Le Clorennec, Christophe, et al.
Publicado: (2016)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT
por: Singh, Bandana, et al.
Publicado: (2021)

Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
por: Kanack, Adam J., et al.
Publicado: (2022)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells
por: Le Clorennec, Christophe, et al.
Publicado: (2019)

A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions
por: Neiveyans, Madeline, et al.
Publicado: (2019)

Monitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab
por: Nugue, Guillaume, et al.
Publicado: (2013)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Evaluating the Synergistic Neutralizing Effect of Anti-Botulinum Oligoclonal Antibody Preparations
por: Diamant, Eran, et al.
Publicado: (2014)

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin
por: Singh, B, et al.
Publicado: (2021)

Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease
por: Corti, Davide, et al.
Publicado: (2016)

Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides
por: Graner, Michael, et al.
Publicado: (2020)

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
por: Mancini, Maicol, et al.
Publicado: (2017)

Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands
por: Tomizawa, Yuji, et al.
Publicado: (2023)

Advances in the applications of monoclonal antibodies in clinical oncology. Abstracts.
Publicado: (1984)

Detection of oligoclonal IgG kappa and IgG lambda bands in cerebrospinal fluid and serum with Hevylite™ antibodies. comparison with the free light chain oligoclonal pattern
por: Zeman, David, et al.
Publicado: (2012)

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL
por: Brazdilova, K, et al.
Publicado: (2018)

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
por: Pelegrin, Mireia, et al.
Publicado: (2015)

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation
por: Perez, Norma, et al.
Publicado: (2004)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

The Combination of Dupilumab with Other Monoclonal Antibodies
por: Gisondi, P., et al.
Publicado: (2022)

Mutant monoclonal antibodies with alterations in biological functions
por: Yelton, DE, et al.
Publicado: (1982)

A combination of two human monoclonal antibodies cures symptomatic rabies
por: de Melo, Guilherme Dias, et al.
Publicado: (2020)

In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies
por: Laustsen, Andreas H., et al.
Publicado: (2018)

The development and characterisation of porphyrin isothiocyanate–monoclonal antibody conjugates for photoimmunotherapy
por: Hudson, R, et al.
Publicado: (2005)

Single cell analysis reveals oligoclonality among “low count” monoclonal B cell lymphocytosis
por: Lanasa, Mark C., et al.
Publicado: (2009)

Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier
por: Lampson, Lois A
Publicado: (2011)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

The use and impact of monoclonal antibody biologics during pregnancy
por: Pham-Huy, Anne, et al.
Publicado: (2021)

Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands
por: Jarius, Sven, et al.
Publicado: (2012)

Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play
por: Lambour, Jennifer, et al.
Publicado: (2016)

Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates
por: Carcenac, M, et al.
Publicado: (2001)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
por: Pierpont, Timothy M., et al.
Publicado: (2018)

Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029
por: Bonnet, Mathilde, et al.
Publicado: (2019)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
por: Manso, Taciana, et al.
Publicado: (2023)

Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID
por: Cusi, Maria Grazia, et al.
Publicado: (2023)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_bh3ho42hvr5glt2qi883fvgtpr